PolyNovo Limited (formerly Calzada limited), Melbourne Australia based company partnered with Prof Toby Coates and Prof John Greenwood to find alternative technology to islet cell transplantation for the treatment individuals with type 1 diabetes (T1D).
A study by Duke University School of Medicine shows Brisk walk is more effective compared with jogging in reducing blood glucose levels in prediabetes individuals. They say high-intensity exercise burns more glucose and moderate intensity exercise burns more fat. A brisk walk of 11.5 miles per week is better than 11.5 miles of jogging for prediabetes individuals. Lead author of the study is Dr. William Kraus, M.D and study findings were published in the journal Diabetologia.
A study by Dr. David Hodson, University of Birmingham says 65% to 80% of islet cells are of beta cells. The study found that just 1 to 10% of beta cells control islet response to blood glucose. Failure of this few cells leads to diabetes. Studies are conducted in mice, rat and human models. Study findings were published in Cell Metabolism.
A study done by researchers from Helmholtz Zentrum Muenchen Germany says women with gestational diabetes (GD) after pregnancy can protect themselves against the development of type 2 diabetes (T2D) by breastfeeding for more than three months. The three months of breastfeeding will bring long-term metabolic changes and gets protection from type 2 diabetes (T2D) for at least 15 years.
Gender is not considered a factor in the international guidelines for the management of type 2 diabetes (T2D). A study done by Alexandra Kautzky-Willer, Medical University of Vienna, Austria says diabetes treatment should be gender specific as risk factors and their effects on type 2 diabetes (T2D) individuals are different with respect to men and women. Researchers say gender-specific factors should be incorporated in the international guidelines for the management of diabetes mellitus. The differences are
A study done by researchers from Sheba Medical Center, Israel found that obesity during teenage is at five-fold death risk from coronary heart disease, three-fold death risk from cardiovascular causes and two-fold death risk from a stroke during later in life. Study findings were published in New England Journal of Medicine on Apr 13, 2016.
FDA approved the Synjardy drug that improves glycemic control in adults with type 2 diabetes (T2D). Synjardy is a single pill combination drug containing empagliflozin and metformin hydrochloride. The drug reduced A1C levels significantly after 24 weeks. The most common side effects of the drug are nausea, vomit and tiredness.
Qtern with metformin combination shows a significant reduction in HbA1c when compared with other combination drugs. The European Commission gave nod for the drug in all 28 member countries and Iceland.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.